Genmab.
Danish healthcare company
- Reports this week
- 0
- Active events
- 1
- Connections
- 49
What's happening
Active this week
Earlier this month
One to three months ago
-
CSG, Novo Nordisk, and Genmab were confirmed as constituents of the STOXX 600 index.Some support3 reports
-
Genmab listed its shares on the stock exchange on August 6, 2026.Some support1 report
-
Genmab, headquartered in Denmark, is issuing interim financial reports and monitoring the Japanese market.Some support1 report
-
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Well supported8 reports1 development inside
-
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Some support1 report
Gone quiet
No new reports in 90+ days-
AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.Well supported3 reports1 development inside
-
A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.Some support6 reports1 development inside
-
Genmab is headquartered in Copenhagen.Well supported9 reports
-
Genmab A/S ADR is now listed on the NASDAQ stock exchange.Some support8 reports
-
Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.Some support1 report
-
Genmab's Board of Directors granted stock units and warrants on June 1, 2026.Some support2 reports
-
FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.Well supported4 reports
-
Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.Speculative1 report
-
Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.Speculative1 report
-
Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.Some support3 reports
-
Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.Some support1 report
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.Some support1 report
-
Genmab faces uncertainty regarding regulatory approvals from the FDA.Some support3 reports
-
Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.Some support1 report
-
Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Genmab this week
News at the entities that move Genmab most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Genmab
-
board of directors StructuralThe Coldwater Area Chamber of Commerce is seeking nominations for its leadership body.Moves Genmab
-
AbbVie OperationalAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves Genmab
-
Johnson & Johnson StructuralP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Genmab
-
Novartis TransactionalNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves Genmab
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Genmab
Connections
The 21 strongest of 49, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Operational
AbbVie and Genmab are actively engaged in joint development, clinical trials, and commercialization planning for cancer therapies, including profit-sharing agreements.
-
FDA Structural
The FDA structurally regulates Genmab's drug development, reviewing submissions and granting designations.
-
Johnson & Johnson Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
board of directors Structural
The Board of Directors formally grants stock units and warrants to Genmab as part of its corporate governance.
-
Janssen Transactional
Genmab and Janssen have entered into a partnership regarding the commercialization of the product daratumumab.
-
Jan Van de Winkel Structural
Jan Van de Winkel serves as the CEO and President of Genmab.
-
Novartis Transactional
Genmab receives royalty revenue from Novartis stemming from their collaboration on Kesimpta.
-
Danish Business Authority Structural
Genmab's operation requires formal registration and compliance with the standards set by the Danish Business Authority.
Show all 21 connections
-
Renaissance Technologies Transactional
Renaissance Technologies has made a current investment in Genmab stock.
-
Nasdaq Structural
Genmab is formally listed and trades its shares on the Nasdaq exchange.
-
TD Cowen Transactional
TD Cowen, a financial research firm, issued a rating upgrade to Buy on Genmab.
-
FED Operational
Genmab's strong financial results influence market sentiment regarding the Federal Reserve's rate hike expectations.
-
Denmark Shared context
Genmab is consistently described as being headquartered in or operating from Denmark.
-
Copenhagen Shared context
Genmab is headquartered and operates from Copenhagen.
-
LinkedIn Mentioned together
Genmab utilizes LinkedIn as a platform for corporate presence and communication.
-
Europe Structural
Genmab is included in the STOXX 600 index, which represents the market structure of Europe.
-
Utrecht Shared context
Genmab maintains R&D facilities located within the city of Utrecht.
-
Truist Financial Mentioned together
Truist Financial began providing investment coverage and analysis on Genmab shares.
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data regarding Genmab.
-
Asia Shared context
Genmab is mentioned in the context of corporate earnings reports related to market sentiment in Asia.
-
Michael Schmidt Mentioned together
No evidence links Michael Schmidt to Genmab in the provided timeline.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
3 eventsJune 2026
18 events- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
- Genmab is headquartered in Copenhagen.
- Genmab A/S ADR is now listed on the NASDAQ stock exchange.
- Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.
- Genmab's Board of Directors granted stock units and warrants on June 1, 2026.
- FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.
- Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.
- Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.
- Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.
- Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.
- Genmab faces uncertainty regarding regulatory approvals from the FDA.
- Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.
- Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.